InsiderSignalSign in

← Insider buys

ARDX

Ardelyx, Inc. · Healthcare

Insiders bought $1.9M of Ardelyx, Inc. in the last 12 months

1 insider bought on 1 day.

$1.9MBought, 12 mo

$4.2MSold, 12 mo

$795.2MMarket cap

ARDX over the last year

Insider buy filed (1 day)

Largest buyers, last 12 months

David M MottDirector · 1 day$1.9M

ARDX after insider buys

3 months after each buy, from the first price a copier could get.

+24.0%Average

+19.6 ptsVs S&P 500

7 of 9Higher

9 buys since 2016 with 3 months of prices.

Every filing

182 insider filings since 2016, newest first

John E Bishop · Insider

$76K−5.9%Aug 25

James Parker Brady · Chief Human Resources Officer

$58K−5.8%Aug 25

Eric Duane Foster · Chief Commercial Officer

$33K−2.0%Aug 25

Mike Kelliher · Chief Business Officer

$30K−2.2%Aug 25

Laura A Williams · Chief Patient Officer

$41K−2.8%Aug 25

Michael Raab · President and CEO

$226K−3.5%Aug 25

Michael Raab · President and CEO

$211K−2.4%Jul 17

Laura A Williams · Chief Patient Officer

$490K−17.8%Jun 22

Michael Raab · President and CEO

$236K−2.4%Jun 17

Eric Duane Foster · Chief Commercial Officer

$50K−2.0%May 22

Mike Kelliher · Chief Business Officer

$45K−2.0%May 22

Laura A Williams · Chief Patient Officer

$44K−2.0%May 22

Michael Raab · President and CEO

$343K−3.0%May 22

Michael Raab · President and CEO

$262K−2.0%May 19

Michael Raab · President and CEO

$262K−2.0%Apr 17

Michael Raab · President and CEO

$243K−2.0%Mar 18

Michael Raab · President and CEO

$261K−2.0%Feb 25

David M Mott · Director

$1.9M+11.0%Feb 23

Michael Raab · President and CEO

$269K−2.0%Feb 23

Joseph James Reilly · Insider

$29K−3.0%Feb 23

Laura A Williams · Insider

$48K−2.0%Feb 23

Mike Kelliher · Insider

$56K−3.0%Feb 23

Eric Duane Foster · Chief Commercial Officer

$61K−2.0%Feb 23

Laura A Williams · Chief Patient Officer

$349K−12.0%Jan 9

Michael Raab · President and CEO

$260K−3.0%Nov 25

Elizabeth A Grammer · Insider

$33K−2.0%Nov 25

Mike Kelliher · Insider

$31K−2.0%Nov 25

Laura A Williams · Chief Patient Officer

$36K−2.0%Nov 25

Eric Duane Foster · Chief Commercial Officer

$32K−2.0%Nov 25

Joseph James Reilly · Insider

$61K−9.0%Nov 25

David M Mott · Director

$726K+7.0%Jun 18

David M Mott · Director

$737K+8.0%Jun 11

David M Mott · Director

$329K+4.0%May 19

David M Mott · Director

$1.6M+19.0%May 5

David M Mott · Director

$389K+4.0%Feb 26

David M Mott · Director

$993K+11.0%Jan 22

David M Mott · Director

$997K+15.0%Dec 23

Michael Raab · President and CEO

$134K−2.0%Nov 27

Michael Raab · President and CEO

$153K−3.0%Nov 22

Laura A Williams · Chief Medical Officer

$35K−2.0%Nov 22

David P. Rosenbaum · Chief Development Officer

$34K−1.0%Nov 22

Justin A Renz · CFO

$25K−2.0%Nov 22

Elizabeth A Grammer · Insider

$34K−4.0%Nov 22

David M Mott · Director

$997K+18.0%Nov 14

David P. Rosenbaum · Chief Development Officer

$166K−5.0%Nov 8

David P. Rosenbaum · Chief Development Officer

$162K−5.0%Nov 6

Michael Raab · President and CEO

$148K−2.0%Oct 31

Michael Raab · President and CEO

$45K−1.0%Oct 15

David P. Rosenbaum · Chief Development Officer

$343K−9.0%Oct 1

David P. Rosenbaum · Chief Development Officer

$33K−1.0%Sep 16

About Ardelyx, Inc.

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.